Stock Events

Stock Events

Bicycle Therapeutics 

$3.99
22
-$0.01-0.25% Tuesday 20:00
+$0.00+0%Tuesday 20:10After hours

Statistics

Day High
4
Day Low
3.99
52W High
9.16
52W Low
3.75
Volume
4,244
Avg. Volume
-
Mkt Cap
279.27M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

2MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-1.41
-1.15
-0.88
-0.62
Expected EPS
-1.24
Actual EPS
-0.62

Financials

-301.66%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
72.59MRevenue
-218.96MNet Income

Analyst Ratings

15.40Average Price Target
The highest estimate is 36.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
40%
Hold
60%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BCYC. It's not an investment recommendation.
Apple
4
AAPL
Amazon
4
AMZN
Bitcoin
4
BTC.CRYPTO
Tesla
3
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Arvinas
ARVN
Mkt Cap586.51M
Arvinas utilizes PROTAC technology for targeted protein degradation, offering an alternative to Bicycle's platform in targeted cancer therapy.
Nektar Therapeutics
NKTR
Mkt Cap2.49B
Nektar Therapeutics works on novel drug conjugates and immune modulators, competing in the same space as Bicycle's innovative cancer treatments.
Adaptive Biotechnologies
ADPT
Mkt Cap3.94B
Adaptive Biotechnologies focuses on the immune-driven discovery and development of cancer therapies, potentially competing with Bicycle's targeted approaches.
Xencor
XNCR
Mkt Cap1.74B
Xencor specializes in engineering monoclonal antibodies for cancer and autoimmune diseases, competing with Bicycle's novel therapeutic platforms.
Allogene Therapeutics
ALLO
Mkt Cap708.26M
Allogene Therapeutics is pioneering allogeneic CAR-T cell therapies, a different but competitive approach to Bicycle's cancer treatment strategies.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is leading in gene editing, offering a fundamentally different but competitive approach to treating diseases targeted by Bicycle.

About

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
Show more...
CEO
Kevin Lee
Employees
288
Country
United Kingdom
ISIN
US0887861088
WKN
000A2PKZC

Listings

XNAS
US
BCYC
STU
DE
50BA.STU
MU
DE
50BA.MU
F
DE
50BA.F

0 Comments

Share your thoughts

FAQ

What is Bicycle Therapeutics stock price today?▼
The current price of BCYC is $3.99 USD — it has decreased by -0.25% in the past 24 hours. Watch Bicycle Therapeutics stock price performance more closely on the chart.
What is Bicycle Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Bicycle Therapeutics stocks are traded under the ticker BCYC.
Is Bicycle Therapeutics stock price growing?▼
BCYC stock has fallen by -1.72% compared to the previous week, the month change is a -5.23% fall, over the last year Bicycle Therapeutics has showed a -44.43% decrease.
What is Bicycle Therapeutics market cap?▼
Today Bicycle Therapeutics has the market capitalization of 279.27M
What were Bicycle Therapeutics earnings last quarter?▼
BCYC earnings for the last quarter are -0.62 USD per share, whereas the estimation was -1.24 USD resulting in a +50% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bicycle Therapeutics revenue for the last year?▼
Bicycle Therapeutics revenue for the last year amounts to 72.59M USD.
What is Bicycle Therapeutics net income for the last year?▼
BCYC net income for the last year is -218.96M USD.
How many employees does Bicycle Therapeutics have?▼
As of August 19, 2026, the company has 288 employees.
In which sector is Bicycle Therapeutics located?▼
Bicycle Therapeutics operates in the Health & Wellness sector.
When did Bicycle Therapeutics complete a stock split?▼
Bicycle Therapeutics has not had any recent stock splits.
Where is Bicycle Therapeutics headquartered?▼
Bicycle Therapeutics is headquartered in CAMBRIDGE, United Kingdom.